002038.SHE Beijing SL Pharmaceutical Co Ltd
- Market cap
- CNY 5.12B
- P/E
- -
- P/B
- 1.06x
- ROE
- -9.7%
- Dividend yield
- 0.35%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 002038.SHE undervalued?
Graham numberThe Graham number of Beijing SL Pharmaceutical Co Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Beijing SL Pharmaceutical Co Ltd fundamental analysis
No fundamental analysis for Beijing SL Pharmaceutical Co Ltd yet.
Beijing SL Pharmaceutical Co Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate;…
Full company profileBeijing SL Pharmaceutical Co Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Beijing SL Pharmaceutical Co Ltd annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.01B | 1.24B | 2.17B | 2.03B | 1.11B | 1.21B | 1.05B | 1.02B | 660M | 624M | 521M |
| Gross Profit | 656M | 876M | 1.72B | 1.61B | 945M | 1.03B | 893M | 830M | 448M | 388M | 300M |
| Operating Income | 507M | 622M | 682M | 561M | 413M | 458M | 263M | 478M | -120M | -2.65M | 21.5M |
| EBITDA | 488M | 410M | 717M | 536M | 239M | 312M | 257M | 365M | 181M | 164M | 21.5M |
| Net Income | 452M | 534M | 571M | 487M | 365M | 426M | 234M | 417M | -74.1M | -347M | -467M |
| EPS | 0.44 | 0.52 | 0.83 | 0.47 | 0.35 | 0.41 | 0.23 | 0.41 | -0.07 | -0.34 | -0.45 |
| Balance Sheet | |||||||||||
| Total Assets | 4.08B | 4.59B | 4.99B | 5.22B | 5.39B | 5.76B | 5.88B | 6.28B | 5.98B | 6.07B | 5.15B |
| Total Liabilities | 151M | 286M | 470M | 404M | 410M | 434M | 397M | 468M | 398M | 883M | 318M |
| Shareholders' Equity | 3.90B | 4.27B | 4.50B | 4.81B | 4.97B | 5.31B | 5.47B | 5.80B | 5.57B | 5.18B | 4.82B |
| Cash & Short-term Investments | 1.21B | 1.51B | 1.20B | 1.40B | 1.44B | 1.64B | 1.45B | 2.13B | 893M | 519M | 464M |
| Total Debt | - | - | - | 3.94M | 5.51M | 2.47M | - | 37.6M | 1.26M | - | - |
| Cash Flow | |||||||||||
| Operating Cash Flow | 397M | 381M | 485M | 666M | 416M | 465M | 390M | 460M | 225M | 258M | - |
| Capital Expenditure | 164M | 230M | 227M | 273M | 256M | 237M | 163M | 218M | 347M | 193M | 25.3M |
| Free Cash Flow | 233M | 151M | 258M | 393M | 160M | 228M | 226M | 242M | -122M | 64.7M | 363M |
| Ratios | |||||||||||
| ROE | 11.6% | 12.5% | 12.7% | 10.1% | 7.3% | 8.0% | 4.3% | 7.2% | -1.3% | -6.7% | -9.7% |
| ROA | 11.1% | 11.6% | 11.5% | 9.3% | 6.8% | 7.4% | 4.0% | 6.6% | -1.2% | -5.7% | -9.1% |
| Net Profit Margin | 44.8% | 43.0% | 26.4% | 24.0% | 32.8% | 35.1% | 22.3% | 40.9% | -11.2% | -55.7% | -89.6% |
| Debt to Equity | - | - | - | 0.00x | 0.00x | 0.00x | - | 0.01x | 0.00x | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Beijing SL Pharmaceutical Co Ltd dividends
- Dividend yield
- 0.35%
- Forward dividend
- 0.01 CNY
- Payout ratio
- -
- Ex-dividend date
- Jul 22, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 17.9M | 0.02 | - |
| 2024 | CNY 154M | 0.15 | - |
| 2023 | CNY 103M | 0.10 | 24.7% |
| 2022 | CNY 103M | 0.10 | 43.8% |
| 2021 | CNY 103M | 0.10 | 24.1% |
| 2020 | CNY 205M | 0.20 | 56.3% |
| 2019 | CNY 548M | 0.53 | 112.6% |
| 2018 | CNY 342M | 0.50 | 59.9% |
| 2017 | CNY 137M | 0.13 | 25.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1.5:1 on Jul 4, 2019.
Who owns Beijing SL Pharmaceutical Co Ltd
- Insiders 40.98%
- Institutions 0.48%
- Public & others 58.54%
- Shares outstanding 1.03B
- Free float 638M
Beijing SL Pharmaceutical Co Ltd company profile
- Company name
- Beijing SL Pharmaceutical Co Ltd
- Ticker
- 002038.SHE
- ISIN
- CNE000001L31
- Exchange
- Shenzhen Stock Exchange
- Listed since
- Aug 25, 2004
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 901
- Fiscal year end
- December
- Address
- Building 1, Bitongyuan, Beijing, China, 100143
- Phone
- 86 10 6872 7127
- Website
- slpharm.com.cn
About Beijing SL Pharmaceutical Co Ltd
Beijing SL Pharmaceutical Co., Ltd., a biopharmaceutical company, research, development, and production of genetic engineering and related drugs People's Republic of China and internationally. The company's finished formulations include temozolomide; arsenic trioxide; lenalidomide capsules; paclitaxel injection; docetaxel injection; thymopentin; vinorelbine tartrate injection; hydroxyl-camptothecine; nimustine hydrochloride; asparaginase; PEG L-asparaginase; calcium foliate; recombinant human basic fibroblast growth factor; liraglutide; insulin aspart 30; insulin aspart 50; insulin aspart; dispersible; ornidazole; voriconazole; adefovir dipivoxil; levofloxacin hydrochloride; azithromycin; ribavirin; tenofovir disoproxil fumarate; valacylovir hydrochloride; lysozyme; stavudine; tropisetron hydrochloride; granisetron hydrochloride; omeprazole; coenzyme complex; ginkgo biloba extract; simvastatin; telmisartan; naftopidil; nicergoline; zaleplon; cytidine disodium triphosphate; febuxostat; filgrastim; recombinant human interleukin-11; and recombinant human interleukin-2 products. The company was formerly known as Beijing BaiLuyuan Bio-Pharmaceutical Co., Ltd and changed its name to Beijing SL Pharmaceutical Co., Ltd. in 1998. Beijing SL Pharmaceutical Co., Ltd. was founded in 1994 and is headquartered in Beijing, the People's Republic of China.
Beijing SL Pharmaceutical Co Ltd management
3- Dr. Mingbo Xu Ph.D.Founder, Non-Independent Chairman & GM · born 1964
- Ms. Li JiAccounting Supervisor & Financial Manager · born 1981
- Ms. Shujie LiangSecretary & Non-Independent Director · born 1966